Ajanta Pharma on Monday said its consolidated profit after tax increased 4% year-on-year to Rs 255 crore in the first quarter ended June 30, 2025, aided by robust sales of branded generics. The Mumbai-based drug maker reported a profit after tax of Rs 246 crore in the June quarter of the last fiscal.
Revenue from operations rose to Rs 1,303 crore in the period under review as compared with Rs 1,145 crore in the year-ago period, Ajanta Pharma said in a regulatory filing.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
The company's sales of branded generics in India, Asia and Africa climbed by 9% year-on-year to Rs 941 crore in the April-June quarter this fiscal.
Sales of generics in the US market stood at Rs 310 crore in the June quarter, a growth of 36% year-on-year, as against Rs 228 crore in the same period last year.
Shares of the company ended 0.99% down at Rs 2,753.65 apiece on the BSE.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.